The team at UAlberta spinoff company Metabolomic Technologies Inc. (from left): Richard Fedorak, Victor Tso, Haili Wang, Gigi Ho, Reg Joseph and Rae Foshaug.
A colon cancer screening test developed at the University of Alberta is on its way to commercialization and potential worldwide use, through a new collaboration with a leading Chinese research institute and a U of A spinoff company.
The groundbreaking research, led by U of A scientists Richard Fedorak and Haili Wang, has the potential to save lives through early and non-invasive diagnosis of precancerous polyps in the colon.
The collaboration, supported by Alberta's Ministry of Enterprise and Advanced Education, enables the spinoff company Metabolomic Technologies Inc. (MTI) to begin validation trials in Canada and China for the promising new diagnostic test, known as PolypDx. BGI Shenzhen, a leading research institute in China, will run validation trials in that country and is partnering with MTI to develop the diagnostic tests for the Chinese market.
The partnership demonstrates the U of A's global impact in discovering and advancing life-saving research, said Lorne Babiuk, vice-president of research.
"The U of A has long been a leader in fundamental research and technology breakthroughs, both of which pave the way for innovations like PolypDx," Babiuk said. "This type of discovery holds immense potential for widespread application and significant health, social and economic advancements here in Alberta and around the world."
PolypDx will eventually be marketed worldwide by MTI, a company formed by Fedorak and Wang with the assistance of the U of A's business incubator, TEC Edmonton.
Fedorak and his team, after developing the simple urine test to detect precancerous polyps, leveraged the U of A's extensive global research network to partner with BGI Shenzhen.
The metabolomics technology, based on metabolites in the body that can be used as biomarkers to determine a person's health, is proving up to 70 per cent more accurate than the fecal-based tests in detecting precancerous polyps in the colon, Fedorak said. In addition, the spot urine sample format of PolypDx will lead to greater patient compliance compared with the fecal-based tests.
Colon cancer is one of the most common types of cancer in the world, yet is preventable and treatable about 90 per cent of the time if detected early in the precancerous polyp stage, he added. The current fecal-based tests tend to detect colon cancer, whereas PolypDx is designed to detect precancerous polyps before they develop into cancer.
"The technology developed through this research with our fellow scientists at BGI opens the door to more easily detecting cancer on a global scale," Fedorak said. "It is something that can ultimately play an important role in preventative management for health care."
Explore further: Estimating the risk of bowel cancer
Medical Xpress on facebook
Related Stories
Estimating the risk of bowel cancer
Aug 19, 2013
Polyps in the mucosa of the colon are a common finding during screening colonoscopies. Some sub-groups of polyps are classed as precursors of bowel cancer. Until now, it has not been possible to precisely ...
Colon cancer screening: Immunological tests are superior
May 28, 2013
Tests for hidden traces of blood ("occult blood") in the stool provide clues to colon cancer or precancerous lesions. For over 40 years, an enzymatic detection method has been used to detect the diseases. Now immunological ...
Gene-based blood test for colon cancer shows promise
Jun 19, 2013
(HealthDay)—Could screening for colon cancer someday be as easy as having a blood test? Researchers say just such a test is showing early promise in trials.
Colon cancer risk when a first-degree relative has precancerous polyps is not clear
May 14, 2012
Current colorectal cancer screening guidelines for individuals with first-degree relatives with precancerous colon polyps are based on studies that were not properly designed or were too limited to shape those guidelines, ...
New 3-D colonoscopy eases detection of precancerous lesions
Jul 31, 2013
MIT researchers have developed a new endoscopy technology that could make it easier for doctors to detect precancerous lesions in the colon. Early detection of such lesions has been shown to reduce death rates from colorectal ...
Recommended for you
Skin cancer death rates 70 percent higher in men
9 minutes ago
(Medical Xpress)—According to research conducted by Cancer Research UK and the University of Leeds, 3.4 men per 100,000 die from malignant melanoma each year in the UK, compared with 2.0 women. But incidence ...
How untying knots promotes cancer
13 hours ago
Researchers have long known that high levels of a specific protein in human cells are linked to tumor growth – but no one has fully understood how.
Study shows survivorship care plans empower cancer patients
13 hours ago
In 2005, the Institute of Medicine, surveying the outlook for the growing number of American cancer survivors, first described the idea of a survivorship care plan: a roadmap for the group of patients, today numbering nearly ...
Chromosome 21 abnormality tells oncologists to treat pediatric ALL more aggressively
16 hours ago
A recent study by members of the Children's Oncology Group reports results of a large trial showing that children whose leukemia cells have amplification of a portion of chromosome 21 may require more aggressive treatment ...
NEETs are prime suspects in breast cancer proliferation
19 hours ago
Two proteins have been identified as prime suspects in the proliferation of breast cancer in a study by an international consortium of researchers from Rice University, the University of North Texas, Denton ...
Team finds potential clue associated with aggressive prostate cancer
22 hours ago
Prostate cancer is one of the most common forms of cancer in men and the leading cause of cancer deaths in white, African-American and Hispanic men, according to the Centers for Disease Control. Current treatment of prostate ...
User comments
© Medical Xpress 2011-2013, Phys.org network
The team at UAlberta spinoff company Metabolomic Technologies Inc. (from left): Richard Fedorak, Victor Tso, Haili Wang, Gigi Ho, Reg Joseph and Rae Foshaug.
A colon cancer screening test developed at the University of Alberta is on its way to commercialization and potential worldwide use, through a new collaboration with a leading Chinese research institute and a U of A spinoff company.
The groundbreaking research, led by U of A scientists Richard Fedorak and Haili Wang, has the potential to save lives through early and non-invasive diagnosis of precancerous polyps in the colon.
The collaboration, supported by Alberta's Ministry of Enterprise and Advanced Education, enables the spinoff company Metabolomic Technologies Inc. (MTI) to begin validation trials in Canada and China for the promising new diagnostic test, known as PolypDx. BGI Shenzhen, a leading research institute in China, will run validation trials in that country and is partnering with MTI to develop the diagnostic tests for the Chinese market.
The partnership demonstrates the U of A's global impact in discovering and advancing life-saving research, said Lorne Babiuk, vice-president of research.
"The U of A has long been a leader in fundamental research and technology breakthroughs, both of which pave the way for innovations like PolypDx," Babiuk said. "This type of discovery holds immense potential for widespread application and significant health, social and economic advancements here in Alberta and around the world."
PolypDx will eventually be marketed worldwide by MTI, a company formed by Fedorak and Wang with the assistance of the U of A's business incubator, TEC Edmonton.
Fedorak and his team, after developing the simple urine test to detect precancerous polyps, leveraged the U of A's extensive global research network to partner with BGI Shenzhen.
The metabolomics technology, based on metabolites in the body that can be used as biomarkers to determine a person's health, is proving up to 70 per cent more accurate than the fecal-based tests in detecting precancerous polyps in the colon, Fedorak said. In addition, the spot urine sample format of PolypDx will lead to greater patient compliance compared with the fecal-based tests.
Colon cancer is one of the most common types of cancer in the world, yet is preventable and treatable about 90 per cent of the time if detected early in the precancerous polyp stage, he added. The current fecal-based tests tend to detect colon cancer, whereas PolypDx is designed to detect precancerous polyps before they develop into cancer.
"The technology developed through this research with our fellow scientists at BGI opens the door to more easily detecting cancer on a global scale," Fedorak said. "It is something that can ultimately play an important role in preventative management for health care."
Explore further: Estimating the risk of bowel cancer
Medical Xpress on facebook
Related Stories
Estimating the risk of bowel cancer
Aug 19, 2013
Polyps in the mucosa of the colon are a common finding during screening colonoscopies. Some sub-groups of polyps are classed as precursors of bowel cancer. Until now, it has not been possible to precisely ...
Colon cancer screening: Immunological tests are superior
May 28, 2013
Tests for hidden traces of blood ("occult blood") in the stool provide clues to colon cancer or precancerous lesions. For over 40 years, an enzymatic detection method has been used to detect the diseases. Now immunological ...
Gene-based blood test for colon cancer shows promise
Jun 19, 2013
(HealthDay)—Could screening for colon cancer someday be as easy as having a blood test? Researchers say just such a test is showing early promise in trials.
Colon cancer risk when a first-degree relative has precancerous polyps is not clear
May 14, 2012
Current colorectal cancer screening guidelines for individuals with first-degree relatives with precancerous colon polyps are based on studies that were not properly designed or were too limited to shape those guidelines, ...
New 3-D colonoscopy eases detection of precancerous lesions
Jul 31, 2013
MIT researchers have developed a new endoscopy technology that could make it easier for doctors to detect precancerous lesions in the colon. Early detection of such lesions has been shown to reduce death rates from colorectal ...
Recommended for you
Skin cancer death rates 70 percent higher in men
9 minutes ago
(Medical Xpress)—According to research conducted by Cancer Research UK and the University of Leeds, 3.4 men per 100,000 die from malignant melanoma each year in the UK, compared with 2.0 women. But incidence ...
How untying knots promotes cancer
13 hours ago
Researchers have long known that high levels of a specific protein in human cells are linked to tumor growth – but no one has fully understood how.
Study shows survivorship care plans empower cancer patients
13 hours ago
In 2005, the Institute of Medicine, surveying the outlook for the growing number of American cancer survivors, first described the idea of a survivorship care plan: a roadmap for the group of patients, today numbering nearly ...
Chromosome 21 abnormality tells oncologists to treat pediatric ALL more aggressively
16 hours ago
A recent study by members of the Children's Oncology Group reports results of a large trial showing that children whose leukemia cells have amplification of a portion of chromosome 21 may require more aggressive treatment ...
NEETs are prime suspects in breast cancer proliferation
19 hours ago
Two proteins have been identified as prime suspects in the proliferation of breast cancer in a study by an international consortium of researchers from Rice University, the University of North Texas, Denton ...
Team finds potential clue associated with aggressive prostate cancer
22 hours ago
Prostate cancer is one of the most common forms of cancer in men and the leading cause of cancer deaths in white, African-American and Hispanic men, according to the Centers for Disease Control. Current treatment of prostate ...
User comments
© Medical Xpress 2011-2013, Phys.org network
0 comments:
Post a Comment